209 related articles for article (PubMed ID: 27870481)
1. Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Denney WS; Denham DS; Riggs MR; Amin NB
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):517-527. PubMed ID: 27870481
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients.
Zhai S; Georgy A; Liang Z; Zhi J
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):552-556. PubMed ID: 27274007
[TBL] [Abstract][Full Text] [Related]
3. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Amin NB; Aggarwal N; Pall D; Paragh G; Denney WS; Le V; Riggs M; Calle RA
Diabetes Obes Metab; 2015 Aug; 17(8):751-9. PubMed ID: 25885172
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
5. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
Peng XV; Marcinak JF; Raanan MG; Cao C
Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
7. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.
Katz L; Manamley N; Snyder WJ; Dodds M; Agafonova N; Sierra-Johnson J; Cruz M; Kaur P; Mudaliar S; Raskin P; Kewalramani R; Pellacani A
Diabetes Obes Metab; 2016 Feb; 18(2):191-5. PubMed ID: 26434934
[TBL] [Abstract][Full Text] [Related]
8. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
Wilding JP; Leonsson-Zachrisson M; Wessman C; Johnsson E
Diabetes Obes Metab; 2013 Aug; 15(8):750-9. PubMed ID: 23464532
[TBL] [Abstract][Full Text] [Related]
9. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM; Park SW; Yoon KH; Min KW; Song KH; Park KS; Park JY; Park IB; Chung CH; Baik SH; Choi SH; Lee HW; Lee IK; Kim DM; Lee MK
Diabetes Obes Metab; 2015 May; 17(5):511-5. PubMed ID: 25523633
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
[TBL] [Abstract][Full Text] [Related]
12. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
13. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
15. Dose selection using a semi-mechanistic integrated glucose-insulin-glucagon model: designing phase 2 trials for a novel oral glucokinase activator.
Zhang X; Schneck K; Bue-Valleskey J; Yeo KP; Heathman M; Sinha V
J Pharmacokinet Pharmacodyn; 2013 Feb; 40(1):53-65. PubMed ID: 23263772
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.
Shankar RR; Bao Y; Han P; Hu J; Ma J; Peng Y; Wu F; Xu L; Engel SS; Jia W
J Diabetes Investig; 2017 May; 8(3):321-329. PubMed ID: 27740719
[TBL] [Abstract][Full Text] [Related]
17. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E
Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
Moses RG; Round E; Shentu Y; Golm GT; O'neill EA; Gantz I; Engel SS; Kaufman KD; Goldstein BJ
J Diabetes; 2016 Sep; 8(5):701-11. PubMed ID: 26625270
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]